Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have given a written, informed consent.~2. Be able and willing to follow instructions, including participation in study assessments, and be present for the required study visits for the duration of the study.~3. Have a best corrected visual acuity.~4. Have a patient-reported history of dry eye in both eyes.~5. Use and/or desire to use an artificial tear substitute for dry eye symptoms within the past 6 months.~6. A negative urine pregnancy test if female of childbearing potential.~7. Have a corneal fluorescein staining score of ≥ 2 in any corneal surface segment in at least one eye at Visit 1.~   -~Exclusion Criteria:~1. Have contraindications to the use of the study drug.~2. Have known allergy or sensitivity to the study drug or components thereof.~3. Have anterior blepharitis.~4. Be diagnosed with an on-going ocular infection or active ocular inflammation.~5. Use contact lenses within 1 week before Visit 1 or during the course of the study.~6. Have previously had Laser-Assisted in Situ Keratomileusis (LASIK) surgery within 12 months prior to Visit 1.~7. Be currently taking any topical ophthalmic prescription or over-the-counter (OTC) solutions, artificial tears, gels, or scrubs and cannot discontinue these medications for the duration of the trial.~8. Have used topical ocular cyclosporine within 30 days prior to Visit 1.~9. Have had a past or present evidence of malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Thymosin Beta 4 (Type: ACTIVE_COMPARATOR): RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
- Placebo (Type: PLACEBO_COMPARATOR): The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.

Based on this trial design, predict the completion outcome and termination type (if applicable).